Spatial Transcriptomics vs. Single-Cell RNA Sequencing: Which Approach Fits Your Research?

Researchers studying gene expression at cellular resolution face a fundamental choice between two complementary technologies. Single-cell RNA sequencing (scRNA-seq) measures the transcriptome of individual cells after they are dissociated from tissue, providing high-resolution snapshots of cellular heterogeneity without location information. Spatial transcriptomics captures gene expression profiles while preserving the spatial coordinates of cells within intact tissue sections, enabling researchers to map where specific transcriptional programs occur. The decision between these approaches depends on whether your research question centers on cellular identity and diversity or on tissue architecture and positional context. This article provides a comparative framework for selecting the appropriate method, with practical guidance on experimental design, data analysis, quality control, and interpretation.

Understanding the Core Distinction Between the Two Technologies

The fundamental difference between scRNA-seq and spatial transcriptomics lies in what each method preserves and what each method sacrifices. scRNA-seq begins with tissue dissociation, a process that breaks down the extracellular matrix and separates cells from their native environment. This dissociation enables the isolation and sequencing of individual cells, yielding transcriptomes at true single-cell resolution. The tradeoff is the complete loss of spatial information. Once a tissue is dissociated, you cannot determine where a particular cell resided within the tissue architecture.

Spatial transcriptomics takes the opposite approach. Tissue sections are preserved intact, and gene expression is measured directly on the section. This preserves the anatomical context of every measurement, allowing researchers to correlate transcriptional activity with tissue structures such as tumor margins, immune infiltrates, or vascular niches. The tradeoff is that many spatial platforms measure gene expression in spots or regions containing multiple cells instead of at true single-cell resolution. Some platforms achieve single-cell or near-single-cell resolution, but they typically capture fewer genes per cell than scRNA-seq.

The two technologies are complementary instead of competitive. scRNA-seq excels at discovering novel cell types and states, while spatial transcriptomics excels at localizing those cell types within tissue and understanding how position influences function. Many research programs use both methods in tandem, with scRNA-seq providing the cellular reference and spatial transcriptomics providing the positional context.

At a Glance: Comparison Table for Method Selection

Core Principles of Single-Cell RNA Sequencing

Tissue Dissociation and Cell Isolation

The scRNA-seq workflow begins with converting solid tissue into a single-cell suspension. This requires enzymatic digestion and mechanical disruption to break down the extracellular matrix and cell-cell adhesions. The choice of dissociation protocol affects which cell types survive and are captured. Fragile cell types, such as neurons or adipocytes, may be lost or damaged during dissociation. Cells that are sensitive to enzymatic treatment may undergo transcriptional changes as a stress response, introducing artifacts into the data.

After dissociation, cells are typically sorted or captured using microfluidic platforms. Microfluidic chips generate high-throughput parallel reaction systems for single-cell screening and analysis, enabling the processing of thousands to hundreds of thousands of cells in a single experiment. The integration and compartmentalization advantages of microfluidic systems have greatly advanced single-cell omics technologies, providing new insights into tissue gene expression profiles and revealing static and dynamic processes in tissues during homeostasis and disease.

Library Preparation and Sequencing

Each captured cell is lysed, and its mRNA is reverse-transcribed into cDNA with a unique barcode that identifies the cell of origin. After amplification and sequencing, the resulting data are processed through a bioinformatics pipeline that assigns reads to cells and genes, generating a count matrix where each row is a gene and each column is a cell.

The analysis workflow typically includes quality control to remove low-quality cells, normalization to account for sequencing depth differences, dimensionality reduction, and clustering to identify cell populations. A central task in scRNA-seq analysis is the calculation of cell type-specific marker genes, which enable researchers to study the differential impact of different conditions on gene regulation and associated networks. Marker gene identification optimizes the ability of the experiment to isolate highly specific cell phenotypes of interest.

Strengths of scRNA-seq

The primary strength of scRNA-seq is its ability to profile the transcriptome of individual cells at scale. This enables the discovery of rare cell populations, the characterization of cellular heterogeneity within a tissue, and the identification of transitional cell states. For example, single-cell transcriptomics has been used to map the spatial distribution of heterogeneous liver endothelial cells in normal versus cirrhotic mouse livers, identifying zone-specific transcriptomic changes associated with cirrhosis. The study identified six clusters of liver endothelial cell populations, including three clusters of liver sinusoidal endothelial cells, and mapped these clusters to specific liver zones based on previously reported landmarks.

scRNA-seq also enables the study of cellular differentiation trajectories. Computational methods such as pseudotime analysis can order cells along a developmental continuum, revealing the transcriptional changes that accompany cell fate decisions. This is particularly valuable for understanding disease progression, where cells may transition through multiple states.

Core Principles of Spatial Transcriptomics

Tissue Preparation and Platform Selection

Spatial transcriptomics begins with tissue sectioning. Fresh-frozen tissue is most commonly used, although some platforms accommodate formalin-fixed paraffin-embedded tissue. The choice of platform determines the resolution, gene capture, and throughput of the experiment.

Several spatial transcriptomics platforms are available, each with distinct characteristics. Some platforms use barcoded capture probes on a slide surface, where tissue sections are placed and mRNA is captured at spatially barcoded spots. Other platforms use imaging-based approaches that visualize individual RNA molecules in situ. The platforms differ in resolution, sample compatibility, and transcriptome depth. For example, some platforms offer whole transcriptome coverage at spot resolution, while others offer targeted gene panels at single-cell resolution.

Measuring Gene Expression in Tissue Context

Spatial transcriptomics simultaneously captures gene expression profiles and the spatial location information of cells. This enables researchers to map molecular gradients, identify tumor-stroma interactions, and localize immune cell populations within the tissue architecture. Unlike bulk RNA sequencing, which masks spatial heterogeneity, spatial transcriptomics retains the architectural context of tumors, enabling the mapping of molecular gradients and immune cell localization.

The analysis of spatial transcriptomics data integrates gene expression profiles with their corresponding spatial locations to identify spatial domains, infer cell-type dynamics, and detect gene expression patterns within tissues. Computational methods have been developed to detect spatial domains, which are regions of tissue with distinct transcriptional programs. These methods leverage spatial information to identify biologically meaningful compartments.

Strengths of Spatial Transcriptomics

The primary strength of spatial transcriptomics is its ability to preserve tissue architecture. This is essential for understanding how position influences cellular function. For example, spatial transcriptomics has been used to study megakaryocyte heterogeneity in murine bone marrow, revealing that the expression of genes associated with platelet production differs between megakaryocytes located in proximal versus distal regions of the bone. This finding would not have been possible with scRNA-seq alone, because the dissociation process removes positional information.

Spatial transcriptomics also enables the study of cell-cell interactions in their native context. By mapping where different cell types are located relative to each other, researchers can infer potential communication pathways and understand how the microenvironment shapes cellular behavior. This is particularly valuable in cancer research, where the tumor microenvironment plays a critical role in disease progression and treatment response.

Practical Workflow for Method Selection

Step 1: Define Your Research Question

Before selecting a method, articulate the specific biological question you aim to answer. If your question is about cellular identity, such as identifying novel cell types or characterizing the transcriptional diversity within a tissue, scRNA-seq is the appropriate choice. If your question is about spatial organization, such as mapping where specific cell populations reside or understanding how the microenvironment influences gene expression, spatial transcriptomics is more suitable.

Consider whether your question requires single-cell resolution. If you need to profile individual cells to distinguish closely related cell states, scRNA-seq provides the necessary resolution. If you need to understand tissue-level patterns, spot-based spatial transcriptomics may be sufficient.

Step 2: Assess Sample Availability and Quality

The condition of your tissue samples influences which method is feasible. scRNA-seq requires viable cells that can survive dissociation and capture. Fresh tissue is essential, and the time between tissue collection and processing should be minimized. Spatial transcriptomics requires intact tissue sections, which can be obtained from fresh-frozen or fixed tissue. Some platforms have specific requirements for tissue preparation, such as optimal cutting temperature embedding for fresh-frozen sections.

For bone tissue, decalcification and processing present unique challenges for spatial transcriptomics. The necessity for bone tissue decalcification and processing imposes tissue-based challenges that must be considered when planning experiments on mineralized tissues.

Step 3: Evaluate Resolution and Gene Capture Requirements

Different spatial platforms offer different tradeoffs between resolution and gene capture. Some platforms provide whole transcriptome coverage at spot resolution, where each spot may contain multiple cells. Other platforms provide single-cell resolution but with targeted gene panels that capture only a subset of the transcriptome. Consider whether you need whole transcriptome coverage or whether a targeted panel is sufficient for your research question.

For scRNA-seq, gene capture is generally high, with thousands of genes detected per cell. This enables unbiased discovery of novel transcripts and cell states. However, the cost per cell increases with sequencing depth, so you must balance the number of cells profiled against the depth of sequencing per cell.

Step 4: Consider Computational Resources and Expertise

Both scRNA-seq and spatial transcriptomics generate large, complex datasets that require specialized bioinformatics analysis. scRNA-seq data analysis involves quality control, normalization, dimensionality reduction, clustering, and marker gene identification. Spatial transcriptomics analysis adds the complexity of spatial coordinates, requiring methods for spatial domain detection, cell-type deconvolution, and spatial statistics.

Assess whether your team has the computational expertise to analyze the data or whether you will need to collaborate with bioinformaticians. Consider the computational resources required for data storage and processing. Spatial transcriptomics datasets can be particularly large, especially for imaging-based platforms that generate high-resolution images.

Step 5: Determine Whether Integration Is Needed

Many research questions benefit from combining both methods. scRNA-seq can provide a cellular reference that guides the interpretation of spatial transcriptomics data. Computational methods have been developed to integrate these data types, using scRNA-seq data for reference-informed detection of biologically interpretable spatial domains. These integrative approaches can substantially improve the accuracy and speed of spatial domain detection compared to analyzing spatial data alone.

For example, a study of vestibular schwannoma integrated scRNA-seq data from three tumors with spatial transcriptomics data from two additional specimens. The integration identified a VEGFA-enriched Schwann cell subtype in the scRNA-seq data that was validated by spatial transcriptomics, revealing that these cells were centrally localized within tumor tissue. This finding demonstrates the power of integrating both methods to achieve a more complete understanding of tumor biology.

Options and Tradeoffs Across Spatial Platforms

Spot-Based Whole Transcriptome Platforms

Spot-based platforms capture mRNA at spatially barcoded spots on a slide surface. Each spot contains multiple cells, and the gene expression profile represents the average of the cells within that spot. These platforms offer whole transcriptome coverage and are relatively straightforward to implement. The main limitation is the lack of single-cell resolution, which can obscure cellular heterogeneity within a spot.

Computational deconvolution methods can estimate cell-type proportions within each spot, but they cannot identify the exact cells needed to reconstruct a single-cell spatial map. More advanced methods use spatially weighted optimal transport to learn a mapping from cells to spots, enabling the inference of both cell-type composition and single-cell spatial maps from spot-based data. These methods can transform abundant spot-resolution data into single-cell resolution, facilitating cell-level discoveries within tissues.

Imaging-Based Single-Cell Platforms

Imaging-based platforms use fluorescence in situ hybridization or similar approaches to visualize individual RNA molecules within intact tissue. These platforms achieve single-cell or subcellular resolution and can capture hundreds to thousands of genes simultaneously. The main limitation is the restricted gene panel, which requires prior knowledge of which genes to include.

Imaging-based platforms are particularly valuable for validating findings from scRNA-seq or for studying known cell types and pathways in a spatial context. They are also well suited for clinical samples where whole transcriptome profiling may not be feasible.

Targeted Versus Whole Transcriptome Approaches

The choice between targeted and whole transcriptome approaches depends on your research question. Targeted panels are more cost-effective and can be designed to capture specific cell types or pathways of interest. Whole transcriptome approaches provide unbiased coverage and enable discovery of novel genes and pathways.

For spatial transcriptomics, targeted panels are often necessary when using imaging-based platforms. For scRNA-seq, whole transcriptome coverage is standard, although targeted approaches are available for specific applications.

Observations and Measurements in Practice

Case Study: Liver Cirrhosis

A study using scRNA-seq to investigate liver cirrhosis mapped the spatial distribution of heterogeneous liver endothelial cells in normal versus cirrhotic mouse livers. The researchers identified six clusters of liver endothelial cell populations, including three clusters of liver sinusoidal endothelial cells. Based on previously reported landmarks, they mapped the three clusters to liver zones 1, 2, and 3 and determined phenotypic changes in each zone between control and cirrhotic mice.

The study found that genes representing capillarization of liver sinusoidal endothelial cells, such as CD34, as well as extracellular matrix genes, were most upregulated in zone 3 in cirrhotic mice. Liver sinusoidal endothelial cells in cirrhotic mice also demonstrated decreased expression of endocytic receptors, most remarkably in zone 3. Transcription factors that induce nitric oxide production in response to shear stress were downregulated in all zones in cirrhotic mice, implying increased intrahepatic vascular resistance.

This study demonstrates how scRNA-seq can provide spatial insights even without direct spatial measurements, by using known anatomical landmarks to map cell populations to tissue zones. However, the approach relies on prior knowledge and cannot capture the full complexity of spatial organization.

Case Study: Placenta Accreta Spectrum Disorder

A study of placenta accreta spectrum disorder used both scRNA-seq and spatially resolved transcriptomics to characterize cellular heterogeneity at the maternal-fetal interface. The study included 12 placentas, 6 with placenta accreta spectrum disorder and 6 controls. For each placenta with the disorder, multiple biopsies were taken at adherent and nonadherent sites in the same placenta.

The study used two platforms to generate libraries: one for single-cell transcriptomes and one for spatially resolved transcriptomes. Differential gene expression analysis was performed using a suite of bioinformatic tools, with correction for multiple testing. In situ hybridization and immunohistochemistry were used to validate findings at the RNA and protein levels.

The results revealed dramatic differences in the transcriptional profile by site of biopsy between placenta accreta spectrum and controls, with most differences noted at the site of adherence. This study illustrates the value of combining both methods to understand how spatial location within a tissue influences disease pathology.

Case Study: Colorectal Cancer Drug Response

A study investigating the antitumor effects of nitidine chloride in colorectal cancer used multiple approaches, including scRNA-seq and spatial transcriptomics, to explore the mechanism of action. The study identified BUB1 as a core downregulated gene and confirmed BUB1 overexpression in colorectal cancer in proliferative and malignant regions using multi-omics approaches.

Immune correlation analysis revealed that high BUB1 expression correlated negatively with antigen presentation molecules, chemokines and receptors, and immune cell infiltration. This study demonstrates how integrating scRNA-seq and spatial transcriptomics can provide mechanistic insights into drug action and identify potential biomarkers for patient stratification.

Records and Data Management

Data Storage and Organization

Both scRNA-seq and spatial transcriptomics generate substantial amounts of raw data. Raw sequencing files, processed count matrices, and analysis outputs must be stored and organized systematically. Establish a naming convention for files that includes the experiment date, sample identifier, and analysis version. Maintain a laboratory information management system or spreadsheet that tracks sample metadata, including tissue source, processing date, and experimental conditions.

Metadata Documentation

Comprehensive metadata is essential for reproducible analysis. Record the tissue type, species, genotype, treatment conditions, and any other relevant information for each sample. For spatial transcriptomics, document the tissue section orientation, the platform used, and the resolution of the measurements. For scRNA-seq, document the dissociation protocol, the capture platform, and the sequencing depth.

Data Sharing and Repositories

Many funding agencies and journals require data deposition in public repositories. The National Center for Biotechnology Information provides data resources for genomic data, including single-cell and spatial transcriptomics datasets. The National Institutes of Health has established a Genomic Data Sharing Policy that outlines expectations for data sharing and access. Familiarize yourself with these requirements before beginning your experiment to ensure compliance.

Reproducibility and Version Control

Document all analysis steps, including software versions and parameter settings. Use version control for analysis scripts and maintain a record of the computational environment used for each analysis. This enables you to reproduce your results and to share your analysis pipeline with collaborators or reviewers.

Quality Control and Quality Assurance

scRNA-seq Quality Metrics

Quality control for scRNA-seq typically involves filtering cells based on the number of genes detected, the total number of reads, and the percentage of reads mapping to mitochondrial genes. Cells with very low gene counts may be empty droplets or damaged cells. Cells with very high mitochondrial read fractions may be stressed or dying. Establish thresholds based on the distribution of these metrics in your data and document the filtering criteria.

Spatial Transcriptomics Quality Metrics

Quality control for spatial transcriptomics includes assessing the total number of reads per spot, the number of genes detected per spot, and the spatial distribution of these metrics. Spots with very low read counts may be located in tissue-free areas or may have poor capture efficiency. Spots with very high read counts may represent tissue regions with high cellular density.

For imaging-based platforms, assess the quality of the images and the specificity of the hybridization signals. Poor image quality or nonspecific binding can compromise the accuracy of the measurements.

Batch Effects and Technical Variation

Both scRNA-seq and spatial transcriptomics are susceptible to batch effects, which are systematic technical variations that occur between experimental batches. These can arise from differences in sample processing, reagent lots, sequencing runs, or other technical factors. Computational methods can correct for batch effects, but the effectiveness of these methods depends on the experimental design.

To minimize batch effects, process samples from different conditions in a balanced manner across batches. Include technical replicates where possible and use computational methods to assess and correct for batch effects during analysis.

Common Failure Patterns and How to Avoid Them

Inadequate Sample Quality

Poor sample quality is a common cause of failed experiments. For scRNA-seq, cells that are damaged or stressed during dissociation may not survive capture or may produce low-quality transcriptomes. For spatial transcriptomics, tissue sections that are degraded or improperly fixed may yield poor capture efficiency.

To avoid these failures, optimize tissue processing protocols for your specific tissue type. Test different dissociation conditions for scRNA-seq and different fixation and embedding conditions for spatial transcriptomics. Assess sample quality before proceeding with the full experiment.

Insufficient Sequencing Depth

Insufficient sequencing depth can result in sparse data with low gene detection, limiting the ability to identify cell types or spatial domains. For scRNA-seq, the number of reads per cell determines the sensitivity of gene detection. For spatial transcriptomics, the number of reads per spot determines the quality of the spatial maps.

To avoid this failure, sequence to a depth appropriate for your research question. Pilot experiments can help determine the optimal sequencing depth for your samples and platform.

Misalignment of Research Question and Method

A common failure is selecting a method that does not match the research question. Using scRNA-seq to study tissue architecture will not provide the spatial information needed. Using spatial transcriptomics to discover novel cell types may be limited by the resolution and gene capture of the platform.

To avoid this failure, carefully consider your research question before selecting a method. If your question requires both cellular resolution and spatial context, consider integrating both methods.

Computational Analysis Bottlenecks

The computational analysis of single-cell and spatial transcriptomics data can be challenging, particularly for researchers without bioinformatics expertise. Analysis pipelines are complex and require careful parameter selection and interpretation.

To avoid this failure, invest in training for your team or collaborate with bioinformaticians. Use established analysis pipelines and document your analysis steps thoroughly.

Limitations and Interpretation Challenges

Technical Limitations of scRNA-seq

scRNA-seq requires tissue dissociation, which can introduce artifacts. The dissociation process can alter gene expression, particularly for genes involved in stress responses and cell adhesion. Some cell types are preferentially lost during dissociation, leading to biased cell-type composition in the data.

The capture efficiency of scRNA-seq is not uniform across all transcripts. Low-abundance transcripts may not be detected, and the sensitivity of detection varies between platforms and protocols. This can limit the ability to detect subtle differences between cell states.

Technical Limitations of Spatial Transcriptomics

Many spatial transcriptomics platforms lack true single-cell resolution. Spot-based platforms measure the average gene expression of multiple cells within each spot, which can obscure cellular heterogeneity. Computational deconvolution methods can estimate cell-type proportions, but these estimates have uncertainty.

The gene capture of spatial transcriptomics platforms varies widely. Some platforms provide whole transcriptome coverage, while others are limited to targeted gene panels. The choice of platform determines the breadth of the transcriptome that can be measured.

Interpretation Challenges

Interpreting spatial transcriptomics data requires careful consideration of the relationship between gene expression and tissue structure. The presence of a gene transcript does not necessarily indicate the presence of the corresponding protein, and post-transcriptional regulation can decouple RNA and protein levels.

For both scRNA-seq and spatial transcriptomics, the data represent a snapshot of gene expression at a single time point. Dynamic processes, such as cell differentiation or disease progression, cannot be directly observed. Computational methods can infer trajectories, but these inferences have limitations.

Integration Challenges

Integrating scRNA-seq and spatial transcriptomics data presents computational challenges. The two data types have different resolutions, gene capture, and noise characteristics. Methods for integration must account for these differences to produce biologically meaningful results.

Some integration methods use scRNA-seq data as a reference to guide the interpretation of spatial data. For example, integrative and reference-informed tissue segmentation methods leverage scRNA-seq data for reference-informed detection of biologically interpretable spatial domains. These methods can improve the accuracy and speed of spatial domain detection, but they require high-quality reference data.

Safety and Regulatory Context

Ethical Considerations for Human Samples

Research involving human tissue samples must comply with ethical and regulatory requirements. Obtain appropriate informed consent from donors and ensure that the research protocol is approved by the relevant institutional review board. The National Institutes of Health Genomic Data Sharing Policy outlines expectations for the sharing of genomic data from human subjects, including requirements for data de-identification and access controls.

Data Privacy and Security

Genomic data from human subjects are sensitive and must be protected. Ensure that data are stored securely and that access is restricted to authorized personnel. When sharing data, comply with applicable privacy regulations and data use agreements.

Biosafety Considerations

Working with human or animal tissue samples requires adherence to biosafety guidelines. Handle samples in appropriate containment facilities and follow standard precautions to prevent exposure to infectious agents. For animal studies, ensure that the research protocol is approved by the institutional animal care and use committee.

Professional Escalation Criteria

When to Seek Bioinformatics Expertise

If your team lacks experience with single-cell or spatial transcriptomics data analysis, seek collaboration with bioinformaticians before beginning your experiment. Analysis challenges that warrant escalation include:

• Difficulty processing or aligning sequencing data
• Uncertainty about quality control thresholds
• Challenges with batch effect correction
• Need for advanced analyses such as trajectory inference or cell-cell communication

When to Seek Platform-Specific Guidance

Each spatial transcriptomics platform has specific requirements for tissue preparation, library preparation, and data analysis. If you are using a platform for the first time, seek guidance from the platform provider or from researchers with experience using that platform. Platform-specific issues that warrant escalation include:

• Poor capture efficiency or low gene detection
• Unexpected spatial patterns in quality metrics
• Difficulty with tissue sectioning or mounting

When to Seek Statistical or Computational Consultation

The analysis of single-cell and spatial transcriptomics data involves complex statistical methods. If you are uncertain about the appropriateness of a statistical test or the interpretation of a computational result, consult with a statistician or computational biologist. Statistical issues that warrant escalation include:

• Uncertainty about multiple testing correction
• Concerns about overfitting in machine learning models
• Difficulty interpreting clustering or dimensionality reduction results

Frequently Asked Questions

What is the main difference between scRNA-seq and spatial transcriptomics?

scRNA-seq measures the transcriptome of individual cells after tissue dissociation, providing high-resolution data on cellular heterogeneity without spatial information. Spatial transcriptomics measures gene expression in intact tissue sections, preserving the spatial coordinates of measurements. The main difference is that scRNA-seq sacrifices spatial context to achieve single-cell resolution, while spatial transcriptomics preserves tissue architecture but may lack true single-cell resolution on many platforms.

Can I use scRNA-seq to determine where cells are located in tissue?

scRNA-seq does not directly provide spatial information because tissue dissociation removes cells from their native environment. However, computational methods can infer spatial locations by mapping cell populations to known anatomical landmarks or by integrating scRNA-seq data with spatial transcriptomics data. These approaches are indirect and require prior knowledge or additional data.

What are the main spatial transcriptomics platforms available?

Several spatial transcriptomics platforms are available, including spot-based whole transcriptome platforms and imaging-based single-cell platforms. Examples include 10x Genomics Visium, Slide-seqV2, MERFISH, NanoString GeoMx DSP, CosMx SMI, and BGI Stereo-seq. These platforms differ in resolution, sample compatibility, and transcriptome depth.

How do I choose between scRNA-seq and spatial transcriptomics for my research?

Consider your research question first. If you need to identify novel cell types or characterize cellular heterogeneity, scRNA-seq is appropriate. If you need to map where cell populations are located or understand how the microenvironment influences gene expression, spatial transcriptomics is appropriate. If your question requires both cellular resolution and spatial context, consider integrating both methods.

What is the cost difference between scRNA-seq and spatial transcriptomics?

The cost of both methods varies depending on the platform, the number of samples, and the sequencing depth. scRNA-seq costs scale with the number of cells profiled, while spatial transcriptomics costs scale with the number of tissue sections and the platform used. Imaging-based platforms with targeted gene panels may be more cost-effective for specific applications, while whole transcriptome approaches are generally more expensive.

Can spatial transcriptomics achieve single-cell resolution?

Some spatial transcriptomics platforms achieve single-cell or near-single-cell resolution, particularly imaging-based platforms that visualize individual RNA molecules. However, these platforms typically capture a limited number of genes compared to whole transcriptome approaches. Spot-based platforms measure the average gene expression of multiple cells within each spot, requiring computational deconvolution to estimate cell-type composition.

How do I integrate scRNA-seq and spatial transcriptomics data?

Integration methods use scRNA-seq data as a reference to guide the interpretation of spatial transcriptomics data. These methods can identify spatial domains, infer cell-type composition, and map single cells to spatial locations. Some methods use spatially weighted optimal transport to learn a mapping from cells to spots, enabling the inference of both cell-type composition and single-cell spatial maps.

What are the main challenges in analyzing spatial transcriptomics data?

Spatial transcriptomics data analysis involves integrating gene expression profiles with spatial coordinates to identify spatial domains and infer cell-type dynamics. Challenges include the lack of single-cell resolution on many platforms, the need for computational deconvolution, and the complexity of spatial statistics. Computational methods continue to improve, but careful parameter selection and interpretation are required.

Related Bioinformatics Guides

• Modern Transcriptomics: From Bulk RNA-Seq to Single-Cell and Spatial Resolution
• Single-Cell RNA-Seq Normalization: Batch Effect Correction and Dimension Reduction (PCA, t-SNE, UMAP)
• Single-Cell RNA Sequencing: From Bulk to Resolution
• Master Guide: Single-Cell RNA Sequencing Bioinformatics Workflows
• Single-Cell RNA-Seq Analysis Pipelines for Veterinary Immunology

References and Further Reading

• EMBL-EBI Training. European Bioinformatics Institute.
• NCBI Data Resources. National Center for Biotechnology Information.
• Genomic Data Sharing Policy. National Institutes of Health.
• The FAIR Guiding Principles. Scientific Data.
• Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis.. Cellular and molecular gastroenterology and hepatology, 2021.
• Integrating single-cell and spatial transcriptomics reveals the cellular heterogeneity of vestibular schwannoma.. NPJ precision oncology, 2025.
• Placenta accreta spectrum disorder at single-cell resolution: a loss of boundary limits in the decidua and endothelium.. American journal of obstetrics and gynecology, 2024.
• Nitidine chloride inhibits colorectal cancer by targeting BUB1: mechanistic insights from molecular dynamics simulation, spatial transcriptomics, and single-cell RNA sequencing.. BMC gastroenterology, 2025.
• Spatial transcriptomics of murine bone marrow megakaryocytes at single-cell resolution.. Research and practice in thrombosis and haemostasis, 2023.
• Integrating single-cell and spatial transcriptomics to dissect mast-cell heterogeneity and arginine-metabolism-associated markers in BRCA.. Neoplasia (New York, N.Y.), 2026.
• SMaSH: a scalable, general marker gene identification framework for single-cell RNA-sequencing.. BMC bioinformatics, 2022.
• CT Radiomics-based Machine Learning to Identify Intratumoral Fibrosis and Underlying Angiogenesis in Hepatocellular Carcinoma.. Radiology, 2026.
• Spatial transcriptomics in Alzheimer's disease: technologies, challenges and discoveries.. 2026.
• Progress in the Application of Machine Learning in the Field of Single-Cell and Spatial Transcriptomics. 2026.
• Multi-Dimensional Transcriptomics Reveals the Prominent Role of Neuroinflammation in Alzheimer's Disease.. 2026.
• HistoMap: Reconstructing Spatially Resolved Single-Cell Profiles from Bulk RNA-Seq to Decipher the Immune-Excluded Microenvironment in Colon Cancer. 2026.
• Emerging Insights into the Principles and Advantages of Single-Cell and Spatial Transcriptomics. Academic Journal of Science and Technology, 2025.
• Advances in Microfluidic Single-Cell RNA Sequencing and Spatial Transcriptomics. Micromachines, 2025.
• Accurate and Efficient Integrative Reference-Informed Spatial Domain Detection for Spatial Transcriptomics. Nature Methods, 2024.
• Multiscale Cell-Cell Interactive Spatial Transcriptomics Analysis. Research Square, 2025.
• Unraveling plant-microbe symbioses using single-cell and spatial transcriptomics.. Trends in Plant Science, 2024.
• Artificial Intelligence-driven spatial transcriptomics in OSCC: Mapping the tumor microenvironment and personalizing therapy. Journal of Oral Biology and Craniofacial Research, 2025.
• Spatial transcriptomics in bone research: navigating hype and hurdles. Pathology (Sydney), 2025.
• Inference of cell-type composition and single-cell spatial maps from spatial transcriptomics data with SWOT. Communications Biology, 2025.
• IGHG1+ malignant epithelial Cell-myCAF crosstalk via MIF-CD74/APP-CD74 drives early brain metastasis in NSCLC: Delineated via primary tumor-brain metastasis single-cell and spatial transcriptomics. Cancer Letters, 2026.
• Single-cell and spatial transcriptomics analyses reveal tumor microenvironment-driven proliferation of NF2-associated vestibular schwannomas. Journal of Neuroinflammation, 2026.

This article is educational and does not replace validated analysis plans, institutional policy, clinical interpretation, or specialist review.